Blog
RSS FeedPosted by Michael Wonder on 28 Apr 2021
Rockwell Medical announces marketing approval of Triferic AVNU in Canada
27 March 2021 - Rockwell Medical today announced that Triferic AVNU (ferric pyrophosphate citrate injection) received a Notice of Compliance (marketing ...
Posted by Michael Wonder on 23 Apr 2021
AbbVie receives Health Canada approval of Humira (adalimumab) for the treatment of paediatric patients with moderately to severely active ulcerative colitis
22 April 2021 - Approval based on results from the pivotal Phase 3 ENVISION I trial, the largest clinical trial in ...
Posted by Michael Wonder on 19 Apr 2021
Darzalex SC becomes the first and only Health Canada approved treatment for patients with newly diagnosed light chain amyloidosis, a rare disease
19 April 2021 - Darzalex SC combination regimen is supported by the Phase 3 ANDROMEDA study demonstrating a significantly higher haematologic ...
Posted by Michael Wonder on 17 Apr 2021
Health Canada authorises Evrysdi (risdiplam) for the treatment of spinal muscular atrophy in adults and children
15 April 2021 - Evrysdi (risdiplam) is the first at home administered treatment for spinal muscular atrophy. ...
Posted by Michael Wonder on 08 Apr 2021
Teva Canada announces new auto-injector for Ajovy for the preventive treatment of migraine in adults
8 April 2021 - Ajovy now offers patients greater flexibility with two dosing options available in both an auto-injector and a ...
Posted by Michael Wonder on 03 Apr 2021
Taltz (ixekizumab) approved by Health Canada for the treatment of paediatric patients (six to less than 18 years of age) with moderate to severe plaque psoriasis
2 April 2021 - On 29 March 2021, Health Canada issued a Notice of Compliance for Taltz (ixekizumab) injection, 80 mg/mL, ...
Posted by Michael Wonder on 23 Mar 2021
Health Canada approves Kesimpta, the first and only self-administered targeted B-cell therapy for relapsing remitting multiple sclerosis
23 March 2021 - Approval is based on two Phase 3 studies (ASCLEPIOS I & II) demonstrating significant reductions in risk ...
Posted by Michael Wonder on 18 Mar 2021
Novartis' Kisqali (ribociclib) product monograph in Canada now includes MONALEESA-3 data demonstrating statistically significant improvement in overall survival in postmenopausal women with HR+/HER2- advanced breast cancer
18 March 2021 - Kisqali is currently the only CDK4/6 inhibitor that has demonstrated statistically significant improvement in overall survival (key ...
Posted by Michael Wonder on 17 Mar 2021
Health Canada approves new indication for lung cancer treatment option Alunbrig
17 March 2021 - First-line indication offers Canadians with advanced lung cancer new treatment options. ...
Posted by Michael Wonder on 17 Mar 2021
Health Canada approves Increlex, first and only recombinant human insulin-like growth factor-1 therapy in Canada for the treatment of severe growth failure associated with ultra rare condition in children and adolescents
16 March 2021 - Ipsen Biopharmaceuticals today announced the commercial availability of Increlex (mecasermin) for the treatment of growth failure in ...
Posted by Michael Wonder on 16 Mar 2021
Health Canada approves Perjeta for use pre-surgery in patients with aggressive early breast cancer
16 March 2021 - New approval provides Canadian patients with HER2 positive early breast cancer a proven treatment regimen in a ...
Posted by Michael Wonder on 08 Mar 2021
Health Canada approves Keytruda (pembrolizumab) as first-line treatment for adults with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer
8 March 2021 - Approval based on significant progression-free survival findings from Phase 3 KEYNOTE-177 trial. ...
Posted by Michael Wonder on 03 Mar 2021
Health Canada approves Brukinsa (zanubrutinib) for the treatment of Waldenström’s macroglobulinaemia
2 March 2021 - Approval is based on the Phase 3 ASPEN trial of Brukinsa compared to ibrutinib. ...
Posted by Michael Wonder on 26 Feb 2021
Emgality (galcanezumab) now approved for use in Canada for the treatment of episodic cluster headache
25 February 2021 - The first and only anti-CGRP treatment with dual indications. ...
Posted by Michael Wonder on 26 Feb 2021
Medexus announces expanded availability of Gleolan in Canada
25 February 2021 - Medexus Pharmaceuticals announced today that it has initiated the commercial launch of Gleolan in Canada, which had ...